Acrivon Therapeutics (ACRV) to Release Earnings on Thursday

Acrivon Therapeutics (NASDAQ:ACRV) is expected to issue its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.66) per share for the quarter.

Acrivon Therapeutics Trading Up 4.7 %

NASDAQ:ACRV opened at $5.61 on Tuesday. The company has a 50-day moving average of $5.54 and a 200-day moving average of $6.65. Acrivon Therapeutics has a twelve month low of $4.69 and a twelve month high of $11.90. The firm has a market cap of $174.67 million, a price-to-earnings ratio of -2.08 and a beta of 0.85.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. KeyCorp initiated coverage on Acrivon Therapeutics in a report on Friday, January 31st. They issued an “overweight” rating on the stock. Cantor Fitzgerald assumed coverage on shares of Acrivon Therapeutics in a research report on Friday, January 31st. They issued an “overweight” rating for the company. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $23.67.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.